Universal Biosensors’ (UBI) core capabilities are technology and product development and manufacturing. UBI's business model is to commercialise products on its platform technology by partnering with market leaders:

  • UBI's first global strategic partnership was established with LifeScan, (a Johnson & Johnson company), soon after the company was founded in 2001.
  • In September 2011, UBI signed a non-exclusive license agreement with Australian company, SpeeDx Pty Ltd for access to its proprietary MNAzyme technology, a highly selective method for detecting sequences of the human genome.
  • In September 2012, UBI signed a long term supply and manufacturing agreement with Siemens Healthcare Diagnostics to manufacture several test strips currently being jointly developed for the point-of-care coagulation market.
  • Universal Biosensors is developing a PT-INR test that can be used in the home and expects to distribute this system by partnering with specialist distributors in this emerging market.